Availability
0
Your Basket is Empty
ND45968

Denufosol tetrasodium NEW

A P2Y2 receptor agonist that has been studied in cystic fibrosis and retinal diseases such as retinal detachment. Denufosol was studied as an inhaled drug for cystic fibrosis, due to its ability to activate an alternative chloride channel and avoiding the defective CFTR chloride channel. This enhances hydration of the lung mucosa and improves mucociliary clearance.  The drug did not progress from phase III clinical trials. Denufosol resulted in subretinal fluid reabsorption in in vivo model of retinal detachment.

Technical Data

CAS No: 318250-11-2
Synonyms: 2'-Deoxycytidine P'''-5'-ester with uridine 5'-(pentahydrogen tetraphosphate) sodium salt; Uridine 5'-(pentahydrogen tetraphosphate), P'5'-ester 2'-deoxycytidine; INS 37217; [[(3S,5R)-5-(4-Amino-2-oxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate
Product Code: ND45968
Chemical Formula: C18H23N5Na4O21P4
Molecular Weight: 861.25

References


  • Farjo R et al (2008). Expression profiling after retinal detachment and reattachment: a possible role for aquaporin-0. Invest Ophthalmol Vis Sci 49(2):511-21.
  • Kellerman D et al (2008). Denufosol: a review of studies with inhaled P2Y(2) agonists that led to Phase 3. Pulm Pharmacol Ther 21(4):600-7.
  • Accurso FJ et al (2011). Denufosol tetrasodium in patients with cystic fibrosis and normal to mildly impaired lung function. Am J Respir Crit Care Med 183(5):627-34.

Solubility

Stability

Further Information


Datasheets

Specification: View
MSDS: View

CAS No:
318250-11-2
Synonyms:
2'-Deoxycytidine P'''-5'-ester with uridine 5'-(pentahydrogen tetraphosphate) sodium salt
Uridine 5'-(pentahydrogen tetraphosphate), P'5'-ester 2'-deoxycytidine
INS 37217
[[(3S,5R)-5-(4-Amino-2-oxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate
Chemical Formula:
Molecular Weight:
861.25
Product Structure
References:
1. Farjo R et al (2008). Expression profiling after retinal detachment and reattachment: a possible role for aquaporin-0. Invest Ophthalmol Vis Sci 49(2):511-21.
2. Kellerman D et al (2008). Denufosol: a review of studies with inhaled P2Y(2) agonists that led to Phase 3. Pulm Pharmacol Ther 21(4):600-7.
3. Accurso FJ et al (2011). Denufosol tetrasodium in patients with cystic fibrosis and normal to mildly impaired lung function. Am J Respir Crit Care Med 183(5):627-34.
Click for Specification
Click for MSDS

For requirements greater than the catalogue prepacks email: enquiries@carbosynth.com

Custom Synthesis

For custom synthesis or special requests email: enquiries@carbosynth.com, call +44 (0)1635 578444 or fill out our contact form

Please Wait...